Shengen Bio Secures Over $110 Million in Series B Financing to Advance Innovative RNAi Therapeutics

Investment界 (ID: pedaily2012) December 9th news: Recently, SANEGENEBIO announced that it hasCompleted over US$110 million in Series B financing,This round of financingLed by a well-known industry institution, with participation from an international sovereign fund, Sino Biopharmaceutical Group, Legend Capital, Vivo Capital, Invus, SymBiosis, Suzhou Oriza Holdings Corporation, Hainan Zhenmai Investment Co., Ltd., and Lake Bleu Capital. The company also received strategic investment from Eli Lilly and Company. Existing shareholders including GL Ventures, Qiming Venture Partners, Tibet Xianfeng Qiyun Investment Advisory Co., Ltd., TF Capital, Oriza Holdings, and Northern Light Venture Capital continue to provide support.The funds raised in this round will be used to leverage the company’s globally leading RNAi drug discovery platform — including the LEAD™ (Ligand and Enhancer Assisted Delivery, a novel ligand and enhancer co-delivery) extrahepatic delivery platform — to advance clinical-stage pipelines into registration studies and expedite the development of multiple pipelines across therapeutic areas.

SANEGENEBIOFounded inIn 2021, leveraging its proprietary RNAi drug discovery platform, the company is committed to developing first-in-class/best-in-class RNAi therapies targeting the liver and extrahepatic tissues. Based on this platform, the company has built a diversified pipeline covering different therapeutic areas such as autoimmune diseases, cardiovascular diseases, metabolic disorders, and obesity, with multiple candidates already in clinical stages. The successful completion of this Series B financing will strongly advance the clinical development and global expansion of the company’s ongoing and planned pipelines, further enabling continuous breakthroughs in the RNAi field.

Dr. Wang Weimin, Founder and CEO of SANEGENEBIO, said:"The completion of Series B financing is an important milestone in the company's development. We are honored to have received support from several top global investment institutions, which not only reflects trust and recognition of the company’s R&D capabilities and corporate vision but also injects critical resources for our long-term growth. SANEGENEBIO remains committed to expanding the application boundaries of RNAi technology through continuous innovation to address unmet clinical needs worldwide. Moving forward, the company will fully advance the global late-stage clinical development of its drug candidates while leveraging the LEAD™ platform to push more transformative drug candidates into clinical stages."